ArticleOncoTargets and therapy2026
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06887803 (A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Significance: Inhibition of both the phosphoinositide 3-kinase delta (PI3Kδ) pathway and Janus kinase (JAK) signaling decreases proliferation of cells from patients with myelofibrosis (MF). Roginolisib is a novel oral conformation-selective PI3Kδ inhibitor and when combined with JAK inhibitors it shows efficacy in primary progenitor cells isolated from MF patients. The biologically effective dose (BED) previously established at the daily 80 mg dose and corresponding to ≥90% target inhibition was well tolerated during the first-in-human (FiH) dose study. This dose of roginolisib was combined with approved JAK inhibitors in MF patients who no longer responded to JAK inhibition. Study Design and Methods: The HEMA-MED trial (NCT06887803) is a prospective, multi-center Phase 1/2 study. The primary objective of this study is to evaluate the tolerability of roginolisib when combined with an approved JAK inhibitor in MF patients. Secondary objectives include: (a) changes in peripheral blood Tregs; (b) splenic response rate (SRR); (c) proportion of patients with a reduction in Total Symptom Score (TSS) as measured by Myelofibrosis Symptom Assessment Form (modified MFSAF version 4). Key Inclusion criteria: (1) diagnosis of primary MF; (2) prior treatment with approved JAK inhibitors for ≥3 months and on a stable dose for ≥1 month prior to starting the add-on treatment. Furthermore, patients must show an unsatisfactory spleen reduction; (3) active symptoms of MF as demonstrated by the presence of a TSS of ≥10; (4) platelet count ≥ 50 × 10 Conclusion: Given the safety profile of roginolisib as monotherapy in patients of the FiH study, the combination of a JAK inhibitor (eg, ruxolitinib) and roginolisib is expected to provide a well-tolerated treatment in patients with MF who are no longer responding to JAK inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.